- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02091115
Consumption of Milk Drink and Constipation
Influence of the Consumption of Milk Drink With Bifidobacterium Animalis in Symptoms of Constipation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To that randomized clinical trial, double blind controlled, were recruited in the city of Teutônia - RS - Brazil, 49 women aged 20-50 years. Patients with pathologies that alter the bowel habits, such as food allergies and intolerances; diabetic women, pregnant, breastfeeding women, gastrointestinal symptoms, gastrointestinal pathologies preliminary, current or recent use of antibiotics, anti-inflammatory, laxatives or other drugs were excluded. Ulcerative colitis, Crohn's disease and irritable bowel syndrome, patients having lactose intolerance or do not like milk drink, besides patients showing them to use other types of probiotic food, prebiotic and symbiotic.
Study participants have been diagnosed with constipation according to the recommendations established by the Rome III criteria (World Gastroenterology Organization) and the Bristol Scale (World Gastroenterology Organization). Answered to a questionnaire on the general data, with questions related to the consumption of fruits and vegetables, meats, milk products, water intake, alcohol intake, smoking and physical activity practice.
Were randomly divided in two groups, one group received probiotic culture dairy drink (intervention group), animalis bifidobacterium, containing 3.2 x 107 and the other group has received dairy drink (control group). Was directed towards participants the consumption of one cup (150 ml) of dairy drink per day, preferably on an empty stomach or morning snack, during period of 60 days. The dairy beverages have been donated by a company, bottled in 1 liter bottles, transported in appropriate thermal boxes and delivered in three stages, every twenty days in the residence of the participants.
After 60 consumption days of dairy beverage new reviews with the participants were conducted, they are nutritional assessment and implemented the Rome III Criteria and Scale Bristol again. To do this the weight, height, waist and hip circumference were measured. To measure was utilized digital balance with capacity of 300 kg and inelastic tape with an extension of 1.5 m. Was recommended for participants to stay barefoot and use light clothing. Thereafter, we calculated the Body Mass Index (BMI), waist-hip ratio and risk for cardiovascular disease, classified according to the parameters established by the World Health Organization (1998).
The guidelines on how consume and storing the dairy drink were provided to the participants before the distribution of products. A dairy beverage should be consumed every day preferentially in the morning, be agitated before consuming, not heat it, stored refrigerated. During the study period, participants were instructed not to change their eating habits, physical activity practice, fluid intake and not make use of other products with probiotic culture.
Quantitative variables were described using mean and standard deviation or median and interquartile range. Categorical variables were described by absolute and relative frequencies. To compare means between groups, Student's t-test for independent samples was applied. In case of asymmetry, the Mann-Whitney test was used. To compare proportions, the chi-square test was applied. To evaluate the ROME III and Bristol-scale pre-and post-intervention, the Wilcoxon test was applied. Data analysis was performed using the Statistical Package for Social Sciences (SPSS) version 18.0. The level of statistical significance was 5% (p ≤ 0.05).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Rio Grande do Sul
-
Lajeado, Rio Grande do Sul, Brazil, 95900-000
- University Center Univates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women
Exclusion Criteria:
- diabetic women,
- pregnant,
- breastfeeding women,
- gastrointestinal symptoms,
- gastrointestinal pathologies preliminary,
- current or recent use of antibiotics, antiinflammatory or other drugs,
- womens with pathologies that alter the bowel habits,
- food allergies and intolerances,
- ulcerative colitis,
- Crohn's disease and irritable bowel syndrome,
- patients having lactose intolerance or do not like milk drink,
- patients showing them to use other types of probiotic food, prebiotic and symbiotic.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Dairy drink
Patients received dairy drink for 60 days and were instructed to consume a glass of 150 mL daily.
|
|
Active Comparator: Dairy drink with probiotic culture
Patients received dairy drink with probiotic culture for 60 days and were instructed to consume a glass of 150 mL daily.
|
The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in symptoms of constipation
Time Frame: Up to two months
|
First application of Rome III criteria and Scale Bristol in July 2013.
And the second measure has occurred after the consumption of dairy drink for 60 days and was held in September 2013.
|
Up to two months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increase in frequency evacuations
Time Frame: Up to two months
|
The frequency evacuations have been questions to participants in July 2013 and after the consumption of dairy drink in September 2013
|
Up to two months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Appearance of feces.
Time Frame: Up to two months
|
Bristol scale been applied in July 2013 and in September 2013
|
Up to two months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thaís R Moreira, Professor, University Center Univates
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 072013 (Other Identifier: Rutgers Cancer Institute of New Jersey)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Pamukkale UniversityRecruiting
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Municipal Hospital of Traditional Chinese MedicineRecruiting
-
Universidade Nova de LisboaCINTESIS - Center for Health Technology and Services ResearchRecruiting
Clinical Trials on Dairy drink
-
Danone ResearchCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Danone ResearchTerminatedAntibiotic-Associated DiarrheaGermany
-
University of California, DavisCompleted
-
Athena Institute, NetherlandsYakult Europe BVUnknownConstipation | Diarrhea
-
Clinical Research Center Kiel GmbHYakult Honsha Co., LTDCompletedAntibiotic-associated DiarrheaGermany
-
Givaudan France NaturalsBioFortisCompleted
-
University of GuelphUniversity of Saskatchewan; Purdue UniversityWithdrawn
-
University of TennesseeCompleted
-
University of KansasDairy Management Inc.CompletedChildhood ObesityUnited States